metaLead Therapeutics

Zurich, Switzerland Founded: 2022 • Age: 4 yrs
Next-generation medications against metal poisoning are developed.
Annual revenue - Latest available
Total funding $170,018 2 rounds
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors - Brand Intelligence

About metaLead Therapeutics

metaLead Therapeutics is a company based in Zurich (Switzerland) founded in 2022 by Michal Shoshan. metaLead Therapeutics has raised $170.02 thousand across 2 funding rounds from investors including Venture Kick.

  • Headquarter Zurich, Switzerland
  • Founders Michal Shoshan
  • Sectors
    Healthcare
  • Phone
    Locked
Operational Areas
Healthcare → Medical Devices & Diagnostics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $170.02 K (USD)

    in 2 rounds

  • Latest Funding Round
    $159.94 K (USD), Seed

    Mar 10, 2023

  • Investors
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of metaLead Therapeutics

metaLead Therapeutics has successfully raised a total of $170.02K across 2 strategic funding rounds. The most recent funding activity was a Seed round of $159.94 thousand completed in March 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in metaLead Therapeutics

metaLead Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Venture Kick.

All
Venture Fund
Investor Description Founded Year Domain Location
University backed startup accelerator
Locked Locked Locked
Premium access

Investor details for metaLead Therapeutics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by metaLead Therapeutics

Investments
Premium access

Investment portfolio details for metaLead Therapeutics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - metaLead Therapeutics

Premium access

Detailed financials for metaLead Therapeutics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Metalead Therapeutics Comparisons

metaLead Therapeutics Primary company
Description
Next-generation medications against metal poisoning are deve...
Location
Zurich, Switzerland
Founded Year
2022
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for metaLead Therapeutics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of metaLead Therapeutics

Premium access

Detailed competitors of metaLead Therapeutics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Metalead Therapeutics

Premium access

Complete news archive for metaLead Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about metaLead Therapeutics

metaLead Therapeutics was founded in 2022.

metaLead Therapeutics is headquartered in Zurich, Switzerland.

metaLead Therapeutics is a funded company, having raised a total of $170.02K across 2 funding rounds to date.

MetaLead Therapeutics was founded in 2022 in Zurich, Switzerland, within the biotechnology sector. Focus is placed on developing treatments for metal poisoning, with operations centered on chelation therapy. The lead compound targets lead (Pb) toxicity, which remains the primary treatment approach. Research and development activities are conducted to advance therapeutic options for heavy metal exposures.

metaLead Therapeutics has 1 investor. Key investors include Venture Kick.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available